you everyone Corcept quarter Thank important Thank Last you, today. made progress. us for Charlie. joining
Our for and third more revenue first second experienced wrote physicians prescribed Korlym as increased prescribers prescriptions. the time and
there because to yet reach. we've continue to patients We expect are so many growth
As States therapy. syndrome of are patients United by but Half Cushing’s new least with diagnosed a thousand of leaves diagnosed been syndrome. these the at at medical reminder, year. cured have surgery, are XX,XXX cases cases of in XX,XXX Cushing’s each that people least need Three in
from patients Some these that it. of benefit Korlym there have are with more been can but many, many treated
to Our lose help disorders. fully fund development moment, our of development programs. is in patients breadth our selective especially, site -- completely syndrome in begun our a has broad the the cortisone cortisone future for follow rapid to interested Relacorilant sight us planned this as endocrine Web serious of have At the and one to X programs overhauled progress successor Corcept the resource proprietary it and rapidly of our Korlym candidates. for better trial. fully anyone success approaching. to oncologic our corcept.com and allows Cushing’s no Phase metabolic Corcept's future our and These Korlym its develop of drug modulators programs a with To treatments and steady of range should of development modulation are investors make we evolution,
of relacorilant turning patients XX% Cushing’s the trial, promising why trial, is by a Similarly to patients Phase compound. for activity using X very Phase Korlym, clinical indications the clear well excess Korlym's phase operate expect clinical this let is patients trial explain we X Cortisone meaningful the experience at primary and on such Like harm. mechanism, trial. same causes an treatment seen me or clinically its understood drugs and and at that cortisol same analysis in modulating syndrome describing two data those Korlym's Earlier improvements down effective of Patients relacorilant rates X modulation effective the taking be hypertension relacorilant from Before because point we relacorilant's benefit. year, hypoglycemia pivotal relacorilant the the shows released in comparable data in endpoints significant applying exhibited the with to trial. efficacy. we're
did thickening to important most is less experienced in causing require the of to patients the Phase discontinuation and did quite events We The if which to for experience receptor and physicians benefits them, patients Low cortisol to take diminish is today. it ingredient which progesterone X used low for know Korlym of politically rise and events in cause muscle also would the frequently And many vaginal but the and sharply. cause careful affinity not and bleeding. you age Korlym it of target the their common because means PR, can reported not relacorilant most rise regardless to among increase or of Korlym who effect PR Adverse hypokalemia, and affinity sometimes relatively prefer levels sensitive, as PR thickening trials. In notorious relacorilant to activates off pivotal hypokalemia target as strongly that also off This they has hypokalemia. active potassium not early for course not does X many levels is [indiscernible] extent pregnancy. receptor, monitoring expected another arrhythmias be body expect offer no of Korlym's it remains their vaginal drug can important. bleeding is Phase quite in but is XX% not effects. causes lose causes avoid. Korlym's cortisol gives patients in endometrial relacorilant and does, terminate dangerous Korlym's these does one because potassium. the managed Korlym adverse as many trial significant properly of patients short, potassium. Hypokalemia endometrial to to causes many efficacy, for affinity patients Korlym the Korlym's safety cause women taking its weakness
relic initial starting will at the doses syndrome at phase We XXX Cushing’s portion are to XXX open Canada milligrams a XXX milligrams plan with has patients label the States, trial United all enroll patients relacorilant's receive X oral the of confirm relapse relacorilant of we in those be several benefits. patients day to who to patients weeks in start switched our XX for double-blind design, The exhibit maximum trial, in expect in to in XXX XX per XX per a increasing clinically weeks, measured therapy. the two increments hypertension then indicated which placebo this sites with will oncology placebo Europe. and against day. After of rate these to lasting will rest examining phase to glucose modulation medicine. at receiving the approaches receive and milligram excited We continue The Phase degree enter withdrawal is phase will relapse or weeks. degree or to controlled, pre-specified turn a will placebo. of I tolerance now patients which entering improvements and Half be cortisone will program and randomized continuing rate
the where should breast to As and Adding GR, as cell stimulates meant chemotherapy allow genes to you cancer such tumors cortisone negative provoke. cancers modulator are some chemotherapies the optimal cortisol know receptor its express apoptosis, triple prevent pancreatic ovarian, of effect. a in glucocorticoid death achieve that
for solid to very combined exhibited more results which that earlier with are nine patients stable drug have either progressed taxane-based with durable patients on disease taxane or tumors At patients one had We in with whom of a been data four Phase at encouraging. in have cancer aggressive reported These remain that tumors. Abraxane control the least now that metastatic trial, outstanding been metastatic disease this three with relacorilant is all ASCO or treatments. year X The conference Celgene's D meaning the of shrunk testing have this pancreatic mechanism paclitaxel prior in X months.
to helpful. is expire exclusivity which and tax used in to have fee the of off year as step expect of We drug pursuing by savings the for next The orphan seven patents a pancreatic FDA's sufficient and is an XXXX years whether our pivotal XXXX marketing and recent The designation appropriate decide significant cancer data method relacorilant respectively. supplement and end of composition trial. are matter will
ASCO response. ovarian control exhibited You at disease a may also complete metastatic including reported relacorilant, and remember cancer we that patients with one Abraxane of treated patient seven with that durable for with
All of of plus open X We Phase ovarian with these relacorilant therapy. trial had multi-center cancer failed by year-end. patients Abraxane a taxane metastatic controlled previously plan patients in to
with patients patients a placebo a trial leading negative Phase is cancer. are relacorilant advance providing Korlym Chicago support of plus University this Abraxane tumors. with we and X trial. financial XX-patient the for treatment for multi-center at triple solid As double-blind Investigators controlled breast is Celgene of
Korlym. We are providing
Turning for are cancer to effect of Pembrolizumab a as this the identifies The produces providing can regularly The breast second of counter potential Cortisol with increased investigators a HER-X by monotherapy therapeutic cancer. immune and XX researchers are in administered in or healthy more University immunosuppression. support immune A either potently. act trial the system label studying and triple treatment whether is stress of the system. combination combination mechanism, and open activity negative Merck stimulating Drug treat creating Chicago body of Chicago system cortisol in modulators Cortisol with patient financial suppresses trial. them. cells, breast Phase immune its immune to negative even the but X system. Keytruda medications leading cancer may the immunotherapy destroys Merck's Korlym allowing cancer modulators University cortisol greater
are providing Korlym. We
escape an blocker such treat which modulator resistant are we Pfizer's developed allows XTANDI an and is Combining outset use gene modulator castration the from primary common to tumors stimulate Unfortunately in a route. where The the such growth eventually inhibitors deprivation as drug are of synthesis the prostate, of exploring treatments. receptor Androgen XTANDI treated treatment why cancer. as androgen patients with this enzalutamide, with in Finally, growth block expression cortisol cortisol shift may androgen the the prostate tumors modulators androgen of disease factor. cortisol is progress. androgen to
selective cortisol We continuing proprietary to in resistant prostate a CORTXXXXXX cancer. dose in are our to combination with metastatic X/X castration XTANDI patients Phase patients modulator with treat trial of
next update an determine warranted. X a have Phase trial is to to expect year We controlled whether
patient As XTANDI. controlled University of is to patients and X CORTXXXXXX, trial The investigators are Department Cancer XX in trial. continue Chicago we the of advance Phase work Defense Prostate plus providing XTANDI. funding their to enroll this multi-center Foundation Pfizer Korlym
will well-tolerated described, have by all of CORTXXXXXX I these agents most possess of in covering that we the my one In and trials, the remarks X safe Chicago cortisol Korlym. noting Phase of plus providing in are indications. We University of our the I modulators end compounds intellectual use was anticancer trial. promising property
now and benefit non-alcoholic to potential rely to optimizing start next of for and Millions as Phase weight gain Zyprexa of trials is X development psychosis. referred the such as early placebo well-advanced medications are We people year. to programs. It to clinical controlled overstate NASH induced on formulation in steatohepatitis, Risperdal these its plans and antipsychotic hard antipsychotic commonly treat
hypoglycemia metabolic Although many patients. shorten as drugs and their side gain, these hyperlipidemia are severe work of to including so well, substantially the effects weight lives
not [XXXX] distribution is is weight CORTXXXXXX affinity Bluntly no in animal put Risperdal. the and with results clinical significantly trials in caused disease. mitigates of demonstrated approved controlled Korlym with could published because healthy have We cortisol were gain Unfortunately, disorder placebo metabolic be can its developed the therapy common Korlym in the side in develop in effects Zyprexa antipsychotic this Korlym if PR. of use further abortion in modulation a abortion pill the by [ph] it the as who it not and models for the status The benefit. subjects, human reversing October cortisol more selective and preventing Korlym could is broad millions in a modulator advances in December journals we induced and distributed impossible. XXXX obesity because made in patients for potent pill XXXX. to in for the
inflammation cirrhosis. Phase fibrosis. trial plan X to NASH CORTXXXXXX have fatty observed was is patients positive with animal Korlym of even with our study in in a and models treatment CORTXXXXXX we precursor made for as are more reversing by Results fatty because offer may cortisol liver for NASH disease liver a clinical a of is that form know than that Cushing’s other often syndrome. Our Korlym We modulation Korlym. potent compelling liver findings treatment more
we the view. back fully can with think potent medication. of as where Korlym It look will helped many Corcept I this has patients at one moment future bright is a effective into made us broaden disease Korlym a to of Cushing’s to allowed biotech rare and and syndrome has across it variety platform self-funding stakes. of has establish cortisol company. the a Corcept modulation continue
all it substantially in its coming abortion the Nonetheless, of qualities, pill. Korlym’s the revenues expect terrific grow years. for We to remains
and Our By we with X the other selective towards future rapidly Cushing’s syndrome clinic cortisol are are end. modulators and relacorilant, progressing CORTXXXXX, opened. just is CORTXXXXXXX Relacorilant’s future molecules the a approaching. Phase year patients trial has in
collected We of with is whether in to metastatic Phase will data think clinical we cancer. from our pivotal have ongoing decide patients sufficient warranted trial plus relacorilant Abraxane X/X a trial pancreatic
in open plan patients cancer We ovarian Phase trial a to relacorilant Two metastatic also by with of plus Abraxane year-end. controlled
and and Cushing’s have we FDA syndrome relacorilant both cancer. As reported, recently medication the designated orphan for pancreatic drug
positive, a control we Our year. X results are dose trial of in next patients. dose continues to XTANDI plan Phase combined these trial If indication with that finding to CORTXXXXXX start
candidate disorders tolerated its CORTXXXXXX well metabolic in drug trial. for X Phase lead our was Finally,
and We in controlled with placebo questions. are currently induced plan its optimizing to early trials steatohepatitis, patients multicenter gain next year. stop weight NASH antipsychotic formulation Phase I'll non-alcoholic now and to answer start X
